← back to search

Jasmine H. Francis

Memorial Sloan Kettering Cancer Center · US
Area of research
Ophthalmology · Radiology, Nuclear Medicine and Imaging
Research interest
Research interests include Ocular Oncology and Treatments, Retinal and Macular Surgery, CNS Lymphoma Diagnosis and Treatment, and Brain Metastases and Treatment.
h-index
41
citations
6,218
works
345
NIH funding
primary concept
email

Recent publications

Characterization of Belantamab Mafodotin–Induced Corneal Changes in Patients With Multiple Myeloma
JAMA Ophthalmology 2025cited by 8position: middledoi
A Phase II Study Assessing Long-term Response to Ibrutinib Monotherapy in Recurrent or Refractory CNS Lymphoma
Clinical Cancer Research 2024cited by 20position: middledoi
Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy
British Journal of Haematology 2024cited by 13position: middledoi
Retinopathy, Optic Neuropathy, and Cataract in Childhood Cancer Survivors Treated With Radiation Therapy: A PENTEC Comprehensive Review
International Journal of Radiation Oncology*Biology*Physics 2023cited by 21position: middledoi
Ocular toxicities of fibroblast growth factor receptor inhibitors: A review
Survey of Ophthalmology 2023cited by 16position: middledoi
Treatment of Retinoblastoma: What Is the Latest and What Is the Future
Frontiers in Oncology 2022cited by 96position: middledoi
Loss of polycomb repressive complex 1 activity and chromosomal instability drive uveal melanoma progression
Nature Communications 2021cited by 60position: middledoi
Molecular Changes in Retinoblastoma beyond RB1: Findings from Next-Generation Sequencing
Cancers 2021cited by 53position: firstdoi
Advanced OCT Analysis of Biopsy-proven Vitreoretinal Lymphoma
American Journal of Ophthalmology 2021cited by 44position: middledoi
Refractive Shifts and Changes in Corneal Curvature Associated With Antibody–Drug Conjugates
Cornea 2021cited by 25position: lastdoi
Immune Checkpoint Inhibitor-Associated Optic Neuritis
Ophthalmology 2020cited by 60position: firstdoi
Efficacy of MEK inhibition in patients with histiocytic neoplasms
Nature 2019cited by 379position: middledoi
Intravitreous Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition
Ophthalmology 2019cited by 32position: firstdoi
Ten-year experience with ophthalmic artery chemosurgery: Ocular and recurrence-free survival
PLoS ONE 2018cited by 96position: firstdoi
Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds
British Journal of Ophthalmology 2018cited by 62position: middledoi
<i>BRAF</i>, <i>NRAS</i>, and <i>GNAQ</i> Mutations in Conjunctival Melanocytic Nevi
Investigative Ophthalmology & Visual Science 2018cited by 39position: firstdoi
GNAQ Mutations in Diffuse and Solitary Choroidal Hemangiomas
Ophthalmology 2018cited by 36position: firstdoi
Efficacy and Toxicity of Intravitreous Chemotherapy for Retinoblastoma: Four-Year Experience
Ophthalmology 2017cited by 135position: firstdoi
Clinical and Morphologic Characteristics of MEK Inhibitor–Associated Retinopathy
Ophthalmology 2017cited by 134position: firstdoi
Risk of Extraocular Extension in Eyes With Retinoblastoma Receiving Intravitreous Chemotherapy
JAMA Ophthalmology 2017cited by 76position: firstdoi
An international survey of classification and treatment choices for group D retinoblastoma
International Journal of Ophthalmology 2017cited by 49position: middledoi
Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma
PLoS ONE 2016cited by 151position: middledoi
Growth of Uveal Melanoma following Intravitreal Bevacizumab
Ocular Oncology and Pathology 2016cited by 29position: firstdoi
The Classification of Vitreous Seeds in Retinoblastoma and Response to Intravitreal Melphalan
Ophthalmology 2015cited by 137position: firstdoi
Advanced Unilateral Retinoblastoma: The Impact of Ophthalmic Artery Chemosurgery on Enucleation Rate and Patient Survival at MSKCC
PLoS ONE 2015cited by 87position: middledoi
Combined, Sequential Intravenous and Intra-Arterial Chemotherapy (Bridge Chemotherapy) for Young Infants with Retinoblastoma
PLoS ONE 2012cited by 91position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

David H. Abramson · Memorial Sloan Kettering Cancer Center18 papers (2012–2022)Brian P. Marr · Columbia University Irving Medical Center6 papers (2012–2018)Y. Pierre Gobin · NewYork–Presbyterian Hospital4 papers (2012–2018)Ira J. Dunkel · National Cancer Institute4 papers (2012–2021)Scott E. Brodie · New York University4 papers (2012–2018) · 3 papers (2017–2018)Alexander N. Shoushtari · Humboldt-Universität zu Berlin3 papers (2017–2021) · 3 papers (2017–2018)Hans E. Grossniklaus · Emory University3 papers (2018–2019) · 3 papers (2020–2025)Carol L. Shields · Newcastle University2 papers (2017–2021)Michael A. Postow · Memorial Sloan Kettering Cancer Center2 papers (2017–2019)Malin Hultcrantz · Memorial Sloan Kettering Cancer Center2 papers (2021–2025)Klaus J. Busam · Memorial Sloan Kettering Cancer Center2 papers (2018–2018) · 2 papers (2017–2018)Emily C. Zabor · Cleveland Clinic2 papers (2017–2018)Korey Jaben · Memorial Sloan Kettering Cancer Center2 papers (2019–2020)Paul B. Chapman · Weill Cornell Medicine2 papers (2017–2020)Francis L. Munier · Fondation Asile des Aveugles2 papers (2015–2017) · 2 papers (2016–2018)